These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24351500)

  • 61. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients.
    Solomon M; Bonafede M; Pan K; Wilson K; Beam C; Chakravarti P; Spiegel B
    Dig Dis Sci; 2011 Oct; 56(10):3024-31. PubMed ID: 21717127
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C.
    García-Samaniego J; Romero M; Granados R; Alemán R; Jorge Juan M; Suárez D; Pérez R; Castellano G; González-Portela C
    World J Gastroenterol; 2013 Mar; 19(12):1943-52. PubMed ID: 23569340
    [TBL] [Abstract][Full Text] [Related]  

  • 63. IgE antibodies to hepatitis C virus core and nonstructural antigens in chronic hepatitis C patients before and after antiviral treatment.
    Silva JPCG; Jesus LS; Isabel Schinoni M; Oliveira IS; Atta MLBS; Atta AM
    Int Immunopharmacol; 2021 Apr; 93():107405. PubMed ID: 33529909
    [TBL] [Abstract][Full Text] [Related]  

  • 64. HCV treatment--no more room for interferonologists?
    Drenth JP
    N Engl J Med; 2013 May; 368(20):1931-2. PubMed ID: 23607592
    [No Abstract]   [Full Text] [Related]  

  • 65. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Peginterferon and ribavirin treatment for hepatitis C virus infection.
    Tsubota A; Fujise K; Namiki Y; Tada N
    World J Gastroenterol; 2011 Jan; 17(4):419-32. PubMed ID: 21274371
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Effect of peginterferon alpha-2a combinated with ribavirin in the treatment of rebound patient with chronic hepatitis C: a case report].
    He Q; Li ZY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Oct; 18(10):794. PubMed ID: 21059303
    [No Abstract]   [Full Text] [Related]  

  • 68. Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection.
    Borroni G; Andreoletti M; Casiraghi MA; Ceriani R; Guerzoni P; Omazzi B; Terreni N; Salerno F
    Aliment Pharmacol Ther; 2008 May; 27(9):790-7. PubMed ID: 18298638
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A government sponsored clinic for the evaluation and treatment of chronic hepatitis C in an underinsured population in Puerto Rico.
    Costas P; Ortiz A; Velázquez V; Torres EA
    P R Health Sci J; 2004 Jun; 23(2 Suppl):41-7. PubMed ID: 16929586
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of patients with dual hepatitis B and C: a step in the right direction.
    Aghemo A; Colombo M
    Gut; 2014 Mar; 63(3):380-1. PubMed ID: 23921890
    [No Abstract]   [Full Text] [Related]  

  • 71. Pegylated interferon treatment in HCV genotype 2 and 3 patients refractory to conventional interferon.
    Aziz S
    J Coll Physicians Surg Pak; 2012 Oct; 22(10):615-6. PubMed ID: 23058141
    [No Abstract]   [Full Text] [Related]  

  • 72. [Hepatitis C and HIV in Spanish prisons].
    Soriano V; González-Lahoz J
    Enferm Infecc Microbiol Clin; 2005 Feb; 23(2):51-2. PubMed ID: 15743572
    [No Abstract]   [Full Text] [Related]  

  • 73. Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C.
    AlQaraawi AM; Sanai FM; Al-Husseini H; Albenmousa A; AlSheikh A; Ahmed LR; Hersi A; Al-Otaibi MM; Syed M; Ali SM; Al-hamoudi W; Alswat KA; Abdo AA
    Dig Dis Sci; 2011 Apr; 56(4):1222-8. PubMed ID: 20931285
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
    Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
    Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of hepatitis B and C in children.
    El-Shabrawi M; Hassanin F
    Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
    [TBL] [Abstract][Full Text] [Related]  

  • 76. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?
    McDonald SA; Innes HA; Hayes PC; Dillon JF; Mills PR; Goldberg DJ; Barclay S; Allen S; Fox R; Fraser A; Kennedy N; Bhattacharyya D; Hutchinson SJ
    J Hepatol; 2015 Feb; 62(2):262-8. PubMed ID: 25195556
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.
    Christensen PB; Krarup HB; Laursen AL; Madsen PH; Pedersen C; Schlichting P; Orholm M; Ring-Larsen H; Bukh J; Krogsgaard K
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1115-9. PubMed ID: 22670704
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
    Coppola N; Pisaturo M; Sagnelli C; Sagnelli E; Angelillo IF
    PLoS One; 2014; 9(4):e94542. PubMed ID: 24728219
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hepatitis C treatment for multimorbid patients with substance use disorder in a primary care-based integrated treatment centre: a retrospective analysis.
    Brunner N; Senn O; Rosemann T; Falcato L; Bruggmann P
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1300-7. PubMed ID: 23571610
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Estimates of HCV-1 patients attaining RVR following dual therapy with peg-interferon and ribavirin.
    Andriulli A; Iacobellis A; Valvano MR; Spirito F; Ippolito A; Bossa F; Terracciano F; Fontana R; Niro G
    Dig Dis Sci; 2013 May; 58(5):1371-82. PubMed ID: 23187978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.